Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

NEW YORK, Sept. 7, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0559874/Post-Traumatic-Stress-Disorder-PTSD-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report identifies the key trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Post-Traumatic Stress Disorder (PTSD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Post-Traumatic Stress Disorder (PTSD) Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post-Traumatic Stress Disorder (PTSD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Post-Traumatic Stress Disorder (PTSD) Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Post-Traumatic Stress Disorder (PTSD) Therapeutics therapeutics market.

- Analysis of key recent licensing and partnership agreements in Post-Traumatic Stress Disorder (PTSD) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 PTSD Therapeutics - Introduction 6

2.1 Disease Overview 6

2.2 Epidemiology 6

2.3 Etiology and Pathophysiology 8

2.4 Signs and Symptoms 10

2.5 Diagnosis 11

2.6 Treatment and Management Options 13

2.6.1 Referral Pathway 15

2.7 GlobalData Pipeline Report Guidance 16

3 PTSD Therapeutics - Market Characterization 17

3.1 PTSD Therapeutics Market Size (2005 - 2010) - Global 17

3.2 PTSD Therapeutics Market Forecast (2010 - 2017) - Global 18

3.3 PTSD Therapeutics Market Size (2005 - 2010) - The US 19

3.4 PTSD Therapeutics Market Forecast (2010 - 2017) - The US 20

3.5 PTSD Therapeutics Market Size (2005 - 2010) - France 21

3.6 PTSD Therapeutics Market Forecast (2010 - 2017) - France 22

3.7 PTSD Therapeutics Market Size (2005 - 2010) - Germany 23

3.8 PTSD Therapeutics Market Forecast (2010 - 2017) - Germany 24

3.9 PTSD Therapeutics Market Size (2005 - 2010) - Italy 25

3.10 PTSD Therapeutics Market Forecast (2010 - 2017) - Italy 26

3.11 PTSD Therapeutics Market Size (2005 - 2010) - Spain 27

3.12 PTSD Therapeutics Market Forecast (2010 - 2017) - Spain 28

3.13 PTSD Therapeutics Market Size (2005 - 2010) - The UK 29

3.14 PTSD Therapeutics Market Forecast (2010 - 2017) - The UK 30

3.15 PTSD Therapeutics Market Size (2005 - 2010) - Japan 31

3.16 PTSD Therapeutics Market Forecast (2010 - 2017) - Japan 32

3.17 Drivers and Barriers for the PTSD Therapeutics Market 33

3.17.1 Drivers for the PTSD Therapeutics Market 33

3.17.2 Barriers for the PTSD Therapeutics Market 33

3.18 Opportunity and Unmet Need Analysis 33

3.19 Key Takeaway 34

4 PTSD Therapeutics - Competitive Assessment 35

4.1 Overview 35

4.2 Strategic Competitor Assessment 35

4.3 Product Profiles for the Major Marketed Products in the PTSD Therapeutics Market 36

4.3.1 Paxil (paroxetine) 36

4.3.2 Zoloft (sertraline hydrochloride) 37

4.4 Key Takeaway 38

5 PTSD Therapeutics - Pipeline Assessment 39

5.1 Overview 39

5.2 Strategic Pipeline Assessment 39

5.3 PTSD Therapeutics Pipeline - Pipeline by Phases of Development 39

5.3.1 PTSD Therapeutics - Phase III Pipeline 40

5.3.2 PTSD Therapeutics - Phase II Pipeline 40

5.3.3 PTSD Therapeutics - Phase I Pipeline 40

5.3.4 PTSD Market - Discovery and Pre - clinical Pipeline 40

5.3.5 Technology Trends Analytic Framework 41

5.4 PTSD Therapeutics Market - Pipeline by Mechanism of Action 43

5.5 Key Takeaway 43

6 PTSD Therapeutics - Clinical Trials Mapping 44

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 44

6.2 Clinical Trials by Phase 45

6.3 Clinical Trials by Trial Status 46

6.4 Prominent Sponsors 47

6.5 Top Companies Participating in PTSD Therapeutics Clinical Trials 49

7 Strategic Assessment 50

7.1 Key Events Impacting the Future Market 50

7.2 PTSD Therapeutics - Implications for Future Market Competition 51

8 PTSD Therapeutics - Future Players 52

8.1 Introduction 52

8.2 Company Profiles 52

8.2.1 Biotie Therapies 52

8.2.2 Sanofi 53

8.2.3 Columbia Northwest Pharmaceuticals 56

9 PTSD Therapeutics - Licensing and Partnership Deals 57

10 PTSD Therapeutics - Appendix 58

10.1 Market Definitions 58

10.2 Abbreviations 58

10.3 Methodology 59

10.3.1 Coverage 59

10.3.2 Secondary Research 59

10.3.3 Forecasting 60

10.3.4 Primary Research 62

10.3.5 Expert Panel Validation 62

10.4 Contact Us 62

10.5 Disclaimer 62

10.6 Bibliography 63

1.1 List of Tables

Table 1: SSRI Prescribing Differences in Anxiety Disorders 13

Table 2: PTSD Therapeutics Market, Global, Revenue ($m), 2005–2010 17

Table 3: PTSD Therapeutics Market, Global, Forecast ($m), 2010–2017 18

Table 4: PTSD Therapeutics Market, The US, Revenue ($m), 2005–2010 19

Table 5: PTSD Therapeutics Market, The US, Forecasts ($m), 2010–2017 20

Table 6: PTSD Therapeutics Market, France, Revenue ($m), 2005–2010 21

Table 7: PTSD Therapeutics Market, France, Forecasts ($m), 2010–2017 22

Table 8: PTSD Therapeutics Market, Germany, Revenue ($m), 2005–2010 23

Table 9: PTSD Therapeutics Market, Germany, Forecasts ($m), 2010–2017 24

Table 10: PTSD Therapeutics Market, Italy, Revenue ($m), 2005–2010 25

Table 11: PTSD Therapeutics Market, Italy, Forecasts ($m), 2010–2017 26

Table 12: PTSD Therapeutics Market, Spain, Revenue ($m), 2005–2010 27

Table 13: PTSD Therapeutics Market, Spain, Forecasts ($m), 2010–2017 28

Table 14: PTSD Therapeutics Market, The UK, Revenue ($m), 2005–2010 29

Table 15: PTSD Therapeutics Market, The UK, Forecasts ($m), 2010–2017 30

Table 16: PTSD Therapeutics Market, Japan, Revenue ($m), 2005–2010 31

Table 17: PTSD Therapeutics Market, Japan, Forecasts ($m), 2010–2017 32

Table 18: PTSD Therapeutics - Phase III Pipeline, 2011 40

Table 19: PTSD Therapeutics - Phase II Pipeline, 2011 40

Table 20: PTSD Therapeutics - Phase I Pipeline, 2011 40

Table 21: PTSD Therapeutics - Discovery and Pre - clinical Pipeline, 2011 40

Table 22: PTSD Therapeutics - Clinical Trials by Country, 2011 44

Table 23: PTSD Therapeutics - Clinical Trials by Phase, 2011 45

Table 24: PTSD Therapeutics - Clinical Trials by Status, 2011 46

Table 25: PTSD Therapeutics, Overall Sponsors, 2011 47

Table 26: PTSD Therapeutics, Most Prominent Sponsors, 2011 48

Table 27: PTSD Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 49

Table 28: Biotie Therapies - CNS, Pipeline, 2011 53

Table 29: Biotie Therapies, Deals 2008 - 2011 53

Table 30: Sanofi CNS Pipeline, 2011 55

Table 31: Sanofi, Deals, 2008 - 2011 56

Table 32: Columbia Northwest Pharmaceuticals, CNS Pipeline 2011 56

Table 33: Columbia Northwest Pharmaceuticals, PTSD pipeline 2011 56

Table 34: Licensing & Partnership Deals, 2008 - 2011 57

1.2 List of Figures

Figure 1: PTSD Lifetime Prevalence in Adolescents (13 - 18 years) 7

Figure 2: PTSD Prevalence in Adults in the US 7

Figure 3: PTSD Treatment Rate 8

Figure 4: PTSD Pathophysiology 9

Figure 5: PTSD, Stress Responses 10

Figure 6: PTSD, Diagnosis and Treatment Pattern 12

Figure 7: PTSD, Treatment Options 13

Figure 8: PTSD, Referral Pathway 15

Figure 9: PTSD Therapeutics Market, Global, Revenue ($m), 2005–2010 17

Figure 10: PTSD Therapeutics Market, Global, Forecast ($m), 2010–2017 18

Figure 11: PTSD Therapeutics Market, The US, Revenue ($m), 2005–2010 19

Figure 12: PTSD Therapeutics Market, The US, Forecast ($m), 2010–2017 20

Figure 13: PTSD Therapeutics Market, France, Revenue ($m), 2005–2010 21

Figure 14: PTSD Therapeutics Market, France, Forecast ($m), 2010–2017 22

Figure 15: PTSD Therapeutics Market, Germany , Revenue ($m), 2005–2010 23

Figure 16: PTSD Therapeutics Market, Germany, Forecast ($m), 2010–2017 24

Figure 17: PTSD Therapeutics Market, Italy, Revenue ($m), 2005–2010 25

Figure 18: PTSD Therapeutics Market, Italy, Forecast ($m), 2010–2017 26

Figure 19: PTSD Therapeutics Market, Spain, Revenue ($m), 2005–2010 27

Figure 20: PTSD Therapeutics Market, Spain, Forecast ($m), 2010–2017 28

Figure 21: PTSD Therapeutics Market, The UK, Revenue ($m), 2005–2010 29

Figure 22: PTSD Therapeutics Market, The UK, Forecast ($m), 2010–2017 30

Figure 23: PTSD Therapeutics Market, Japan, Revenue ($m), 2005–2010 31

Figure 24: PTSD Therapeutics Market, Japan, Forecast ($m), 2010–2017 32

Figure 25: Opportunity and Unmet Need in the PTSD Therapeutics Market, 2010 34

Figure 26: PTSD Therapeutics - Strategic Competitor Assessment, 2010 35

Figure 27: PTSD Therapeutics - Pipeline by Phase of Development, 2011 39

Figure 28: PTSD Therapeutics - Technology Trends Analytics Framework, 2011 41

Figure 29: PTSD Therapeutics - Technology Trends Analytics Framework - Description, 2011 42

Figure 30: PTSD Therapeutics - Pipeline by Mechanism of Action (%), 2011 43

Figure 31: PTSD Therapeutics - Clinical Trials by Country, 2011 44

Figure 32: PTSD Therapeutics - Clinical Trials by Phase, 2011 45

Figure 33: PTSD Therapeutics - Clinical Trials by Status, 2011 46

Figure 34: PTSD Therapeutics - Overall Sponsors, 2011 47

Figure 35: PTSD Therapeutics - Prominent Sponsors, 2011 48

Figure 36: PTSD Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 49

Figure 37: PTSD Therapeutics Market, Drivers and Barriers, 2011 50

Figure 38: Implications for Future Market Competition in the PTSD Market, 2011 51

Figure 39: PTSD Therapeutics Market - Pipeline by Company, 2010 52

Figure 40: GlobalData Market Forecasting Model 61

Companies Mentioned

Biotie Therapies

Sanofi

Columbia Northwest Pharmaceuticals

To order this report:

Pathology Industry: Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker